BioNTech (NASDAQ:BNTX – Get Rating) posted its earnings results on Monday. The company reported $15.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.16 by $5.87, reports. BioNTech had a return on equity of 142.70% and a net margin of 54.20%. The company had revenue of $6.37 billion for the quarter, compared to analysts’ expectations of $4.50 billion. During the same period last year, the business posted $5.29 earnings per share. The firm’s quarterly revenue was up 211.2% compared to the same quarter last year.
Shares of BioNTech stock traded up $5.75 during trading on Wednesday, hitting $150.18. 30,695 shares of the stock traded hands, compared to its average volume of 1,943,112. The stock has a market cap of $37.07 billion, a P/E ratio of 3.25 and a beta of -0.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.18 and a current ratio of 4.33. BioNTech has a twelve month low of $121.32 and a twelve month high of $464.00. The company has a fifty day moving average price of $157.49 and a two-hundred day moving average price of $205.50.
The company also recently declared a — dividend, which will be paid on Friday, June 17th. Stockholders of record on Friday, June 3rd will be issued a dividend of $1.5342 per share. The ex-dividend date is Thursday, June 2nd. This represents a dividend yield of 1.1%.
A number of equities research analysts recently weighed in on BNTX shares. Redburn Partners upgraded shares of BioNTech from a “sell” rating to a “neutral” rating in a research note on Tuesday, February 1st. HC Wainwright cut their price objective on shares of BioNTech from $339.00 to $298.00 and set a “buy” rating on the stock in a research note on Tuesday, April 12th. Morgan Stanley lowered their target price on BioNTech from $217.00 to $197.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Canaccord Genuity Group lowered their target price on BioNTech from $450.00 to $300.00 and set a “buy” rating on the stock in a report on Tuesday, April 5th. Finally, Zacks Investment Research lowered BioNTech from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 27th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $259.59.
About BioNTech (Get Rating)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
- Inflation Hasn’t Peaked At Reynolds Consumer Products
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.